Akoya Biosciences, Inc. (AKYA)
USD 2.45
(-3.54%)
USD 2.45
(-3.54%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -50.89 Million | -53.49 Million | -36.06 Million | -6.84 Million | -13.77 Million |
| Net Income | -63.32 Million | -70.64 Million | -42.93 Million | -16.7 Million | -14.75 Million |
| Depreciation & Amortization | 8.89 Million | 7.14 Million | 4.79 Million | 3.81 Million | 3.05 Million |
| Deferred income taxes | -51 Thousand | 35 Thousand | -155 Thousand | 7000.00 | 156 Thousand |
| Stock-based compensation | 10.43 Million | 7.43 Million | 4.03 Million | 477 Thousand | 153 Thousand |
| Change in working capital | -12.05 Million | 2.16 Million | -4.56 Million | 2.39 Million | -1.37 Million |
| Other non-cash items | 5.2 Million | 367 Thousand | 2.75 Million | 3.17 Million | -1.01 Million |
| Investing Cash Flow | 3.34 Million | -14.07 Million | -5.09 Million | 6.72 Million | -12.89 Million |
| Investments in PPE | -3.65 Million | -7.36 Million | -5.09 Million | -3.29 Million | -2.86 Million |
| Acquisitions | - | 55 Thousand | - | 145 Thousand | - |
| Investment purchases | - | -40.77 Million | - | -145 Thousand | -10 Million |
| Sales/Maturities of investments | 7 Million | 34 Million | - | 10.16 Million | - |
| Other Investing Activities | 7 Million | -6.71 Million | - | -145 Thousand | -23 Thousand |
| Financing Cash Flow | 56.84 Million | 28.72 Million | 137.03 Million | 5.48 Million | 28.56 Million |
| Debt repayment | -10.54 Million | -621 Thousand | -322 Thousand | -25.19 Million | -25.04 Million |
| Dividends payments | - | - | -1.43 Million | - | - |
| Common Stock Repurchased | -94 Thousand | - | - | - | - |
| Common Stock Issuance | 48.31 Million | 447 Thousand | 138.94 Million | 122 Thousand | 24.82 Million |
| Other Financing Activities | 19.07 Million | 28.9 Million | 137.35 Million | 30.55 Million | 28.77 Million |
| Accounts receivables | -7.26 Million | -285 Thousand | -2.97 Million | 6.69 Million | -3.37 Million |
| Accounts payables | 1.14 Million | 1.19 Million | 4.36 Million | -3.04 Million | -49 Thousand |
| Inventory | -6.33 Million | -5.37 Million | -4.62 Million | -684 Thousand | -4 Million |
| Other working capital | 391 Thousand | 6.63 Million | -1.32 Million | -574 Thousand | 6.05 Million |
| Cash at beginning of period | 74.22 Million | 113.38 Million | 17.5 Million | 12.13 Million | 10.24 Million |
| Cash at end of period | 83.12 Million | 74.53 Million | 113.38 Million | 17.5 Million | 12.13 Million |
| Capital Expenditure | -3.65 Million | -7.36 Million | -5.09 Million | -3.29 Million | -2.86 Million |
| Effect of forex changes on cash | -396 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 8.89 Million | -38.84 Million | 95.87 Million | 5.37 Million | 1.89 Million |
| Free Cash Flow | -54.55 Million | -60.85 Million | -41.16 Million | -10.13 Million | -16.64 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -13.14 Million | -23.48 Million | -63.32 Million | -10.8 Million | -12.91 Million | -20.8 Million |
| Depreciation & Amortization | 1.92 Million | 2.05 Million | 8.89 Million | 2.1 Million | 2.57 Million | 2.08 Million |
| Deferred income taxes | - | 37 Thousand | -51 Thousand | -51 Thousand | -2.19 Million | 2.19 Million |
| Stock-based compensation | 2.71 Million | 2.56 Million | 10.43 Million | 2.56 Million | 2.87 Million | 2.62 Million |
| Change in working capital | -3.78 Million | -8.21 Million | -12.05 Million | -452 Thousand | -7.76 Million | 227 Thousand |
| Other non-cash items | 14.69 Million | 18.08 Million | 5.2 Million | 1.08 Million | 3.67 Million | 1.87 Million |
| Investing Cash Flow | 9.05 Million | -48.81 Million | 3.34 Million | -594 Thousand | -832 Thousand | -1.42 Million |
| Investments in PPE | -170 Thousand | -810 Thousand | -3.65 Million | -594 Thousand | -832 Thousand | -1.42 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -21.77 Million | -48 Million | - | - | - | - |
| Sales/Maturities of investments | 31 Million | - | 7 Million | - | - | - |
| Other Investing Activities | 9.22 Million | -48 Million | 7 Million | - | - | - |
| Financing Cash Flow | -2.12 Million | -444 Thousand | 56.84 Million | 11.04 Million | -141 Thousand | 46.32 Million |
| Debt repayment | -173 Thousand | -181 Thousand | -10.54 Million | -11.03 Million | -175 Thousand | -173 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -65 Thousand | -149 Thousand | -94 Thousand | 94 Thousand | - | - |
| Common Stock Issuance | 23 Thousand | 36 Thousand | 48.31 Million | 7000.00 | -76 Thousand | 48.21 Million |
| Other Financing Activities | -1.97 Million | -299 Thousand | 19.07 Million | 22.07 Million | 110 Thousand | -1.71 Million |
| Accounts receivables | -3.62 Million | 3.14 Million | -7.26 Million | -898 Thousand | -3.23 Million | 77 Thousand |
| Accounts payables | -962 Thousand | -1.02 Million | 1.14 Million | -114 Thousand | 158 Thousand | 3.04 Million |
| Inventory | -2.28 Million | -7.31 Million | -6.33 Million | 708 Thousand | -2.99 Million | -3.9 Million |
| Other working capital | 3.08 Million | -3.02 Million | 391 Thousand | -148 Thousand | -1.69 Million | 1 Million |
| Cash at beginning of period | 13.03 Million | 83.12 Million | 74.22 Million | 78.59 Million | 93.65 Million | 60.55 Million |
| Cash at end of period | 8.92 Million | 13.03 Million | 83.12 Million | 83.12 Million | 78.92 Million | 93.65 Million |
| Capital Expenditure | -170 Thousand | -810 Thousand | -3.65 Million | -594 Thousand | -832 Thousand | -1.42 Million |
| Effect of forex changes on cash | - | - | -396 Thousand | -369 Thousand | -1.33 Million | - |
| Net cash flow / Change in cash | -4.11 Million | -70.08 Million | 8.89 Million | 4.53 Million | -14.72 Million | 33.1 Million |
| Free Cash Flow | -11.21 Million | -21.63 Million | -54.55 Million | -6.14 Million | -14.58 Million | -13.22 Million |
PVW
CBG-R
MFA-PB
AX8
HEHSF
000240